The demo attained both of those its Main endpoints, with semaglutide 2.4 mg demonstrating statistically important and outstanding enhancements in liver fibrosis without having worsening of steatohepatitis, and resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH in comparison with placebo.1Very good luck! Plan your